Second-quarter 2025 Cost of Sales(3) as a percentage of revenues increased by 0.9 percentage points compared to the prior-year quarter, driven primarily by the non-recurrence of a favorable revision ...
The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...
The MarketWatch News Department was not involved in the creation of this content. -- Strengthened Commercial Execution Driving Topline Growth -- Continued Progress Across R&D Pipeline -- Expanded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback